DALLAS, March 5, 2025 — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), today announced that Ramesh Arjunji, PhD, has joined Nanoscope as Executive Vice President of Value and Access. Dr. Arjunji brings a breadth of experience including commercialization, R&D, medical affairs and business development gained from various leadership positions in the biopharmaceutical industry.
“In addition to his diverse industry experience spanning ophthalmology, neurology, oncology, immunology and medical devices, Ramesh has been an important market access leader for some of the most successfully commercialized gene therapies. We look forward to his contributions as we make preparations to launch MCO-010 as the first restorative treatment for retinitis pigmentosa patients,” said Sulagna Bhattacharya, Nanoscope Co-Founder and CEO.
“I have had the privilege of guiding multiple gene therapies to market, ensuring they reach the greatest number of patients in need. I am excited to leverage my expertise to help Nanoscope achieve similar success in bringing life-changing treatments to those who need them most,” said Dr. Arjunji.
Prior to joining Nanoscope, Dr. Arjunji served as Senior Vice President, Global Value and Access at Krystal Biotech. Prior to Krystal, he was Vice President and Head, Evidence Synthesis at SSI Strategy where he advised clients on evidence generation strategies. Before SSI Strategy, Dr. Arjunji was Vice President, Value & Access at Avrobio, leading the development and execution of evidence generation strategies for lysosomal storage disorders gene therapy products. Prior to Avrobio, Mr. Arjunji worked for AveXis/Novartis Gene Therapies where he led strategy and execution of global HTA engagement for ZOLGENSMA, a gene therapy for spinal muscular atrophy. Dr. Arjunji has also held leadership positions at GSK, Alcon, BMS, Biogen, Pfizer, Endo Pharmaceuticals, and Centocor/Johnson and Johnson. He holds a Doctor of Philosophy in Management Science, Marketing and Statistics from the University of Texas, a Master of Science in Mechanical Engineering from Florida State University, and a Bachelor of Technology in Aeronautics from the Indian Institute of Technology.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com
SOURCE Nanoscope Therapeutics